Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

BACKGROUND: Recent studies have reported improved diastolic function in patients administered sodium-glucose cotransporter 2 inhibitors (SGLT2i). We aimed to investigate the effect of dapagliflozin on left ventricular (LV) diastolic function in a diabetic animal model and to determine the molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Seul-Gee, Kim, Darae, Lee, Jung-Jae, Lee, Hyun-Ju, Moon, Ro-kyung, Lee, Yong-Joon, Lee, Seung-Jun, Lee, Oh-Hyun, Kim, Choongki, Oh, Jaewon, Lee, Chan Joo, Lee, Yong-ho, Park, Seil, Jeon, Ok-Hee, Choi, Donghoon, Hong, Geu-Ru, Kim, Jung-Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450279/
https://www.ncbi.nlm.nih.gov/pubmed/36068525
http://dx.doi.org/10.1186/s12916-022-02485-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450279/
https://www.ncbi.nlm.nih.gov/pubmed/36068525
http://dx.doi.org/10.1186/s12916-022-02485-z

Ejemplares similares